Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

ATTAIN-J

Eli Lilly · Phase 3 · Completed · Enrollment 238

NCT05931380

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

1545.961.4
≥5%
3.3318.0335.09
≥10%
09.8422.81
≥15%
03.2812.28
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Placebo QD15%3.33%0%0%
6 mg Orforglipron QD45.9%18.03%9.84%3.28%
12 mg Orforglipron QD61.4%35.09%22.81%12.28%
36 mg Orforglipron QDn/rn/rn/rn/r

Not shown

  • 36 mg Orforglipron QD: endpoint not reported